General Information of Drug (ID: DM7VTQO)

Drug Name
Entecavir Drug Info
Synonyms
Baraclude; ETV; Entecavir hydrate; Entecavir monohydrate; BMS-200475; Baraclude (TN); Entecavir (INN); Entecavir (USAN); Entecavir hydrate (JAN); SQ-34676; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate
Indication
Disease Entry ICD 11 Status REF
Hepatitis B virus infection 1E51.0 Approved [1]
Therapeutic Class
Antiviral Agents
Cross-matching ID
PubChem CID
135398508
ChEBI ID
CHEBI:473990
CAS Number
142217-69-4
TTD ID
D0KR2J
VARIDT ID
DR01277
ACDINA ID
D00232

Full List of Drug Formulations Containing This Drug

Entecavir 1 mg tablet
Company Formulation ID FDA Description
Teva Pharmaceuticals F07310 Fd&c red no. 40; Fd&c blue no. 2; Magnesium stearate; Mannitol; Ferric oxide yellow; Talc; Titanium dioxide; Polyethylene glycol 3350; Polyethylene glycol 4000; Crospovidone, unspecified; Microcrystalline cellulose; Polyvinyl alcohol, unspecified; Starch, corn
Camber Pharmaceuticals F07307 Calcium carbonate; Sodium stearyl fumarate; Citric acid monohydrate; Ferric oxide red; Titanium dioxide; Carboxymethylcellulose sodium; Hypromelloses; Starch, corn; Thiamine mononitrate
Par Pharmaceutical F07313 Lactose monohydrate; Fd&c yellow no. 6; Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Crospovidone (12 mpa.s at 5%); Crospovidone, unspecified; Microcrystalline cellulose; Peg-2 stearate; Polyvinyl alcohol (100000 mw)
Par Pharmaceutical F07315 Lactose monohydrate; Magnesium stearate; Ferric oxide red; Titanium dioxide; Crospovidone; Polyethylene glycol 400; Cellulose, microcrystalline; Hypromelloses; Povidones
Cadila Healthcare; Zydus Pharmaceuticals F07308 Lactose monohydrate; Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Crospovidone; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
Amneal Pharmaceuticals; Marlex Pharmaceuticals F07309 Lactose monohydrate; Magnesium stearate; Ferric oxide red; Titanium dioxide; Povidone; Cellulose, microcrystalline; Crospovidone (12 mpa.s at 5%); Hypromelloses; Polyethylene glycol 8000
Cipla; NorthStar Rx F07312 Lactose monohydrate; Magnesium stearate; Ferric oxide red; Titanium dioxide; Polyethylene glycol 400; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hypromellose 2910 (6 mpa.s); Povidones
E.R. Squibb & Sons F07314 Lactose monohydrate; Magnesium stearate; Ferric oxide red; Titanium dioxide; Polyethylene glycol 400; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hypromelloses; Povidones
Aurobindo Pharma; Lucid Pharma F07306 Lactose monohydrate; Magnesium stearate; Titanium dioxide; Crospovidone; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
AvKARE F07311 Lactose monohydrate; Magnesium stearate; Ferric oxide red; Titanium dioxide; Cellulose, microcrystalline; Crospovidone (12 mpa.s at 5%); Hypromelloses; Polyethylene glycol 8000; Povidones
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Formulation(s)
Entecavir 0.5 mg tablet
Company Formulation ID FDA Description
Camber Pharmaceuticals F07296 Calcium carbonate; Sodium stearyl fumarate; Citric acid monohydrate; Titanium dioxide; Carboxymethylcellulose sodium; Polysorbate 80; Polyethylene glycols; Starch, corn; Thiamine mononitrate
Teva Pharmaceuticals F07300 Magnesium stearate; Mannitol; Talc; Titanium dioxide; Polyethylene glycol 3350; Crospovidone, unspecified; Microcrystalline cellulose; Polyvinyl alcohol, unspecified; Starch, corn
Par Pharmaceutical F07305 Lactose monohydrate; Magnesium stearate; Titanium dioxide; Crospovidone; Polyethylene glycol 400; Polysorbate 80; Cellulose, microcrystalline; Hypromelloses; Povidones
E.R. Squibb & Sons F07304 Lactose monohydrate; Magnesium stearate; Titanium dioxide; Polyethylene glycol 400; Polysorbate 80; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hypromelloses; Povidones
Cadila Healthcare; Zydus Pharmaceuticals F07297 Lactose monohydrate; Magnesium stearate; Talc; Titanium dioxide; Crospovidone; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
Aurobindo Pharma; Lucid Pharma F07295 Lactose monohydrate; Magnesium stearate; Titanium dioxide; Crospovidone; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
Amneal Pharmaceuticals; Marlex Pharmaceuticals F07298 Lactose monohydrate; Magnesium stearate; Titanium dioxide; Povidone; Cellulose, microcrystalline; Crospovidone (12 mpa.s at 5%); Hypromelloses; Polyethylene glycol 8000
Cipla; NorthStar Rx F07302 Lactose monohydrate; Magnesium stearate; Titanium dioxide; Polyethylene glycol 6000; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hypromellose 2910 (15 mpa.s); Povidones
Par Pharmaceutical F07303 Lactose monohydrate; Magnesium stearate; Titanium dioxide; Polysorbate 80; Crospovidone (12 mpa.s at 5%); Hypromellose, unspecified; Microcrystalline cellulose; Peg-2 stearate; Povidone, unspecified
American Health Packaging F07299 Lactose monohydrate; Magnesium stearate; Titanium dioxide; Crospovidone (15 mpa.s at 5%); Hypromellose, unspecified; Microcrystalline cellulose; Polyethylene glycol, unspecified
AvKARE F07301 Lactose monohydrate; Magnesium stearate; Titanium dioxide; Cellulose, microcrystalline; Crospovidone (12 mpa.s at 5%); Hypromelloses; Polyethylene glycol 8000; Povidones
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Formulation(s)

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.